Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help
Search by PDB author
4R1Y
DownloadVisualize
BU of 4r1y by Molmil
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitor
Descriptor: 2-(2-(2-(2-(2-(2-ETHOXYETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHOXY)ETHANOL, 3-(diethylamino)propyl (3-{[5-(3,4-dimethoxyphenyl)-2-oxo-2H-1,3,4-thiadiazin-3(6H)-yl]methyl}phenyl)carbamate, Hepatocyte growth factor receptor
Authors:Blaukat, A, Bladt, F, Friese-Hamim, M, Knuehl, C, Fittschen, C, Graedler, U, Meyring, M, Dorsch, D, Stieber, F, Schadt, O.
Deposit date:2014-08-08
Release date:2015-03-18
Last modified:2024-02-28
Method:X-RAY DIFFRACTION (2 Å)
Cite:Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Bioorg.Med.Chem.Lett., 25, 2015
4R1V
DownloadVisualize
BU of 4r1v by Molmil
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
Descriptor: 3-[1-(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl}benzyl)-6-oxo-1,6-dihydropyridazin-3-yl]benzonitrile, GAMMA-BUTYROLACTONE, Hepatocyte growth factor receptor
Authors:Blaukat, A, Bladt, F, Friese-Hamim, M, Knuehl, C, Fittschen, C, Graedler, U, Meyring, M, Dorsch, D, Stieber, F, Schadt, O.
Deposit date:2014-08-07
Release date:2015-03-18
Last modified:2024-02-28
Method:X-RAY DIFFRACTION (1.2 Å)
Cite:Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
Bioorg.Med.Chem.Lett., 25, 2015
8AUP
DownloadVisualize
BU of 8aup by Molmil
Structure of hARG1 with a novel inhibitor.
Descriptor: (4S)-2-METHYL-2,4-PENTANEDIOL, 2-[(1~{R},3~{R},4~{S})-3-azanyl-3-carboxy-4-[(dimethylamino)methyl]cyclohexyl]ethyl-$l^{3}-oxidanyl-bis(oxidanyl)boron, Arginase-1, ...
Authors:Napiorkowska-Gromadzka, A, Nowak, E, Nowotny, M.
Deposit date:2022-08-25
Release date:2023-03-29
Last modified:2024-02-07
Method:X-RAY DIFFRACTION (2.17 Å)
Cite:Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy.
Mol.Cancer Ther., 22, 2023
6OMU
DownloadVisualize
BU of 6omu by Molmil
Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib
Descriptor: 1-[4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidin-1-yl]prop-2-en-1-one, CHLORIDE ION, Tyrosine-protein kinase BTK
Authors:Mochalkin, I, Gardberg, A.S.
Deposit date:2019-04-19
Release date:2019-08-14
Last modified:2023-10-11
Method:X-RAY DIFFRACTION (1.41 Å)
Cite:Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
J.Med.Chem., 62, 2019

221051

PDB entries from 2024-06-12

PDB statisticsPDBj update infoContact PDBjnumon